Replies to post #56296 on Biotech Values

[DewDiligence]

>MNTA – I do not expect b) [FoB legislation in 2008] occurring; however, this is a small issue since I expect it shall occur by mid 2009.<

I said 2008 because the discussion pertained to a 12-month forecast. But mid-2009 would work just as well because MNTA will not have an application for a protein drug to submit to the FDA before then.

>Regarding case 2 valuation: the approval will also have the immediate effect of validating MNTA's characterization platform somewhat, which is worth something. You may have already included that in your valuation.<

That’s correct. (Please see my reply to dewophile.)

>We need a RMF.<

I agree. What are you waiting for? :-)